The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

CPD Why do we need new options for managing FH?

Publication date: Tuesday, 19 August 2014
Contributor(s): Alan Rees, Atul Kalhan, Vinay Eligar

In patients with both homozygous and heterozygous familial hypercholesterolaemia (FH), statins with or without ezetimibe are now the mainstay pharmacological therapy for lowering low-density lipoprotein cholesterol (LDL-C) levels, combined with lipoprotein apheresis in homozygotes and statin-refractory heterozygotes. These therapies have helped to improve outcomes, but new treatment options are
urgently needed, as FH patients continue to be at high risk of premature death due to cardiovascular disease (CVD).

HUK_logo_smallcmyk_HR
HEART UK - The Cholesterol Charity - has provided editorial support and review of this sponsored FH series.



SANOFI_Logo_Horizontal_2011_4colors
This article was made possible by an unrestricted educational grant by Sanofi, who had no control over content.

Sponsorship information:
This article was made possible by an unrestricted educational grant by Sanofi, who had no control over content.
Category: Editorial
Edition: Volume 7 Number 3 Oct-Nov-Dec 2014
Print edition page(s): 143
Contributor(s): Alan Rees, Atul Kalhan, Vinay Eligar

Article search and filter